comparemela.com

Latest Breaking News On - Health care facility operation - Page 1 : comparemela.com

Gastro Care Partners Completes Affiliation with Gastroenterology Associates of Wyoming

Uniting Experience with Vision: Johnson Controls unveils OpenBlue Buildings as a Service

Press release content from PR Newswire. The AP news staff was not involved in its creation. Uniting Experience with Vision: Johnson Controls unveils OpenBlue Buildings as a Service April 15, 2021 GMT Johnson Controls Logo. (PRNewsFoto/JOHNSON CONTROLS, INC.) (PRNewsFoto/) MILWAUKEE, April 15, 2021 /PRNewswire/ Johnson Controls (NYSE: JCI), the global leader for smart, healthy and sustainable buildings, today announced OpenBlue Buildings as a Service. Aligning more than 135 years of experience with its OpenBlue digital transformation vision, OpenBlue Buildings as a Service enables Johnson Controls and its customers to be more agile in delivering outcome-based decisions centered around integrated data to help reach environmental stewardship goals.

Joerns Healthcare Selected by Bristol Hospice as Sole Source Medical Equipment Service Partner

Press release content from PR Newswire. The AP news staff was not involved in its creation. Joerns Healthcare Selected by Bristol Hospice as Sole Source Medical Equipment Service Partner April 15, 2021 GMT Joerns Healthcare (PRNewsFoto/Joerns Healthcare) CHARLOTTE, N.C., April 15, 2021 /PRNewswire/ Joerns Healthcare, LLC, a leading medical equipment services company to the care continuum, announced today that they have entered into a sole source agreement with Bristol Hospice, LLC. Joerns Healthcare’s hospice integrated business system was a key value-driver for the agreement. The pairing of Joerns Healthcare’s capability as an integrated service provider and manufacturer to provide standardized products and services in a timely, customer-centric manner, with Bristol, one of the fastest growing hospice agencies in the country with a reputation for exceptional patient and family services, is seen as a powerful partnership.

The Rockefeller Foundation Launches $20 Million Initiative to Increase Covid-19 Vaccination Rates Among Communities of Color

Press release content from PR Newswire. The AP news staff was not involved in its creation. The Rockefeller Foundation Launches $20 Million Initiative to Increase Covid-19 Vaccination Rates Among Communities of Color April 13, 2021 GMT NEW YORK, April 13, 2021 /PRNewswire/ The Rockefeller Foundation announces the launch of a historic $20 million Equity-First Vaccination Initiative to improve the vaccination rate among communities of color, which have been disproportionately impacted by the Covid-19 pandemic. Representing less than one-third of the 74 million people who are now fully vaccinated in the United States, communities of color are twice as likely to die from Covid-19 and three times as likely to be hospitalized as white Americans. To close this gap, the Foundation will initially collaborate with five organizations to deploy equity-first, hyper-local public health interventions in five U.S. cities: Baltimore, Md.; Chicago, Ill.; Houston, Texas; Newark, N.J.; Oakland, Cal

The Latest: CDC head warns against surging shots to Michigan

Don t miss the big stories. Like us on Facebook.   CANBERRA, Australia — Australian authorities have identified a second case of a rare blot clot likely linked to the AstraZeneca coronavirus vaccine. Officials said Tuesday the woman is in her 40s and is in a stable condition. A 44-year-old man developed the same condition following an AstraZeneca injection March 22. Australia has administered 700,000 doses of the AstraZeneca vaccine since early March. That equates to a clotting frequency of 1-in-350,000 cases. British authorities say the risk of such blood clots has been 1-in-250,000 in that country. Australia had planned to rely on Australian-manufactured AstraZeneca for delivering at least one dose of a vaccine to all eligible adults among its population of 26 million by October. But it said last week the Pfizer vaccine is now the preferred option for people under 50 because of the potential risk from AstraZeneca.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.